BR112013008017A2 - análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral - Google Patents
análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviralInfo
- Publication number
- BR112013008017A2 BR112013008017A2 BR112013008017A BR112013008017A BR112013008017A2 BR 112013008017 A2 BR112013008017 A2 BR 112013008017A2 BR 112013008017 A BR112013008017 A BR 112013008017A BR 112013008017 A BR112013008017 A BR 112013008017A BR 112013008017 A2 BR112013008017 A2 BR 112013008017A2
- Authority
- BR
- Brazil
- Prior art keywords
- carbosucleoside
- analogues
- fluorine
- substituted
- antiviral treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/885,917 US7973013B2 (en) | 2009-09-21 | 2010-09-20 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
US13/050,820 US8455451B2 (en) | 2009-09-21 | 2011-03-17 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
PCT/US2011/029441 WO2012039791A1 (en) | 2010-09-20 | 2011-03-22 | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013008017A2 true BR112013008017A2 (pt) | 2016-06-14 |
Family
ID=47748238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013008017A BR112013008017A2 (pt) | 2010-09-20 | 2011-03-22 | análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP2619206A1 (pt) |
JP (4) | JP2013538230A (pt) |
KR (1) | KR101879887B1 (pt) |
CN (1) | CN103108876A (pt) |
AP (1) | AP3699A (pt) |
AU (1) | AU2011306066B2 (pt) |
BR (1) | BR112013008017A2 (pt) |
CA (1) | CA2807496C (pt) |
CL (1) | CL2013000727A1 (pt) |
CO (1) | CO6680669A2 (pt) |
CR (1) | CR20130172A (pt) |
EA (1) | EA026523B1 (pt) |
EC (1) | ECSP13012560A (pt) |
IL (1) | IL225221A0 (pt) |
MA (1) | MA34593B1 (pt) |
MX (1) | MX2013003179A (pt) |
NZ (1) | NZ608070A (pt) |
PE (3) | PE20131165A1 (pt) |
SG (1) | SG188223A1 (pt) |
WO (1) | WO2012039791A1 (pt) |
ZA (1) | ZA201301042B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101645742B1 (ko) | 2008-04-23 | 2016-08-04 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 카바-뉴클레오사이드 유사체 |
SI2480559T1 (sl) | 2009-09-21 | 2013-10-30 | Gilead Sciences, Inc. | Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov |
ES2524398T3 (es) | 2010-07-19 | 2014-12-09 | Gilead Sciences, Inc. | Métodos para la preparación de profármacos de fosforoamidato diastereoméricamente puros |
WO2012012776A1 (en) | 2010-07-22 | 2012-01-26 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
JP5891241B2 (ja) | 2010-12-20 | 2016-03-22 | ギリアード サイエンシーズ, インコーポレイテッド | Hcvを処置するための組合せ |
TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
UA119050C2 (uk) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類 |
CN104230985B (zh) * | 2014-09-01 | 2017-01-18 | 北京天弘天达医药科技有限公司 | (s)‑2‑[(s)‑(4‑硝基‑苯氧基)‑苯氧基‑磷酰基氨基]丙酸异丙酯的制备方法 |
TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
HUE056470T2 (hu) | 2014-12-26 | 2022-02-28 | Univ Emory | Vírusellenes N4-Hidroxicitidin származékok |
CN114366745A (zh) | 2015-09-16 | 2022-04-19 | 吉利德科学公司 | 治疗沙粒病毒科和冠状病毒科病毒感染的方法 |
KR102460968B1 (ko) | 2017-03-14 | 2022-11-01 | 길리애드 사이언시즈, 인코포레이티드 | 고양이 코로나바이러스 감염의 치료 방법 |
ES2938859T3 (es) | 2017-05-01 | 2023-04-17 | Gilead Sciences Inc | Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato |
TW201919648A (zh) | 2017-07-11 | 2019-06-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物 |
GB2590198B (en) | 2017-12-07 | 2022-02-23 | Univ Emory | N4-hydroxycytidine derivatives and anti-viral uses related thereto |
TW202313067A (zh) | 2020-01-27 | 2023-04-01 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
JP2023516087A (ja) | 2020-03-12 | 2023-04-17 | ギリアード サイエンシーズ, インコーポレイテッド | 1’-シアノヌクレオシドを調製する方法 |
CN115362004A (zh) | 2020-04-06 | 2022-11-18 | 吉利德科学公司 | 1’-氰基取代的碳核苷类似物的吸入制剂 |
JP2023528810A (ja) | 2020-05-29 | 2023-07-06 | ギリアード サイエンシーズ, インコーポレイテッド | レムデシビル治療方法 |
KR20230028486A (ko) | 2020-06-24 | 2023-02-28 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오시드 유사체 및 이의 용도 |
TW202228722A (zh) | 2020-08-27 | 2022-08-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之化合物及方法 |
WO2023167944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
WO2023207942A1 (zh) * | 2022-04-25 | 2023-11-02 | 北京沐华生物科技有限责任公司 | 用于治疗或预防冠状病毒感染的核苷类药物及其用途 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
DE69129650T2 (de) | 1990-09-14 | 1999-03-25 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
WO2001032153A2 (en) | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
EP1296690A2 (en) | 2000-02-18 | 2003-04-02 | Shire Biochem Inc. | METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
CN101862345B (zh) | 2000-10-18 | 2014-06-04 | 吉利德制药有限责任公司 | 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物 |
CA2434386C (en) * | 2001-01-22 | 2006-12-05 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
EP1438054A4 (en) | 2001-09-28 | 2006-07-26 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION |
JP2006519753A (ja) | 2002-11-15 | 2006-08-31 | イデニクス(ケイマン)リミテツド | 2’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異 |
SI2604620T1 (sl) * | 2003-05-30 | 2016-10-28 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Modificirani fluorirani nukleozidni analogi |
PT3109244T (pt) | 2004-09-14 | 2019-06-04 | Gilead Pharmasset Llc | ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados |
CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA-依赖性RNA病毒感染的氟化吡咯并[2,3-d]嘧啶核苷 |
US20080280842A1 (en) * | 2004-10-21 | 2008-11-13 | Merck & Co., Inc. | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection |
WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
US8431695B2 (en) | 2005-11-02 | 2013-04-30 | Bayer Intellectual Property Gmbh | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
AU2007342367B2 (en) | 2007-01-05 | 2012-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
US8440813B2 (en) | 2007-01-12 | 2013-05-14 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
US8188272B2 (en) | 2007-03-21 | 2012-05-29 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
WO2008141079A1 (en) | 2007-05-10 | 2008-11-20 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer |
KR101645742B1 (ko) * | 2008-04-23 | 2016-08-04 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 카바-뉴클레오사이드 유사체 |
WO2010036407A2 (en) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
WO2010002877A2 (en) * | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
NZ594370A (en) * | 2009-02-10 | 2014-01-31 | Gilead Sciences Inc | Carba-nucleoside analogs for antiviral treatment |
ME02656B (me) * | 2009-09-21 | 2017-06-20 | Gilead Sciences Inc | 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje |
-
2011
- 2011-03-22 AP AP2013006767A patent/AP3699A/en active
- 2011-03-22 SG SG2013011325A patent/SG188223A1/en unknown
- 2011-03-22 EP EP11715792.5A patent/EP2619206A1/en not_active Withdrawn
- 2011-03-22 MX MX2013003179A patent/MX2013003179A/es not_active Application Discontinuation
- 2011-03-22 CN CN2011800449231A patent/CN103108876A/zh active Pending
- 2011-03-22 PE PE2013000530A patent/PE20131165A1/es active IP Right Grant
- 2011-03-22 BR BR112013008017A patent/BR112013008017A2/pt not_active Application Discontinuation
- 2011-03-22 CA CA2807496A patent/CA2807496C/en active Active
- 2011-03-22 PE PE2022003082A patent/PE20230684A1/es unknown
- 2011-03-22 PE PE2017001530A patent/PE20171624A1/es unknown
- 2011-03-22 AU AU2011306066A patent/AU2011306066B2/en active Active
- 2011-03-22 JP JP2013529139A patent/JP2013538230A/ja not_active Withdrawn
- 2011-03-22 EA EA201390141A patent/EA026523B1/ru unknown
- 2011-03-22 KR KR1020137010012A patent/KR101879887B1/ko active IP Right Grant
- 2011-03-22 NZ NZ608070A patent/NZ608070A/en unknown
- 2011-03-22 WO PCT/US2011/029441 patent/WO2012039791A1/en active Application Filing
-
2013
- 2013-02-07 ZA ZA2013/01042A patent/ZA201301042B/en unknown
- 2013-02-26 CO CO13038918A patent/CO6680669A2/es not_active Application Discontinuation
- 2013-03-14 IL IL225221A patent/IL225221A0/en unknown
- 2013-03-18 CL CL2013000727A patent/CL2013000727A1/es unknown
- 2013-04-04 MA MA35795A patent/MA34593B1/fr unknown
- 2013-04-17 CR CR20130172A patent/CR20130172A/es unknown
- 2013-04-18 EC ECSP13012560 patent/ECSP13012560A/es unknown
-
2016
- 2016-01-18 JP JP2016006833A patent/JP2016074732A/ja not_active Withdrawn
-
2017
- 2017-04-10 JP JP2017077366A patent/JP6475280B2/ja active Active
-
2018
- 2018-09-18 JP JP2018173758A patent/JP2019014726A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CO6680669A2 (es) | 2013-05-31 |
EA026523B1 (ru) | 2017-04-28 |
AP2013006767A0 (en) | 2013-03-31 |
JP2013538230A (ja) | 2013-10-10 |
AP3699A (en) | 2016-05-31 |
CL2013000727A1 (es) | 2013-08-23 |
KR20130110168A (ko) | 2013-10-08 |
JP2017119726A (ja) | 2017-07-06 |
SG188223A1 (en) | 2013-04-30 |
PE20230684A1 (es) | 2023-04-21 |
MX2013003179A (es) | 2013-04-24 |
MA34593B1 (fr) | 2013-10-02 |
AU2011306066A1 (en) | 2013-02-28 |
PE20131165A1 (es) | 2013-10-14 |
CR20130172A (es) | 2013-05-29 |
CA2807496C (en) | 2019-01-22 |
KR101879887B1 (ko) | 2018-07-18 |
JP2019014726A (ja) | 2019-01-31 |
CA2807496A1 (en) | 2012-03-29 |
ZA201301042B (en) | 2014-07-30 |
EA201390141A1 (ru) | 2013-09-30 |
CN103108876A (zh) | 2013-05-15 |
JP6475280B2 (ja) | 2019-02-27 |
JP2016074732A (ja) | 2016-05-12 |
IL225221A0 (en) | 2013-06-27 |
AU2011306066B2 (en) | 2015-01-29 |
EP2619206A1 (en) | 2013-07-31 |
WO2012039791A1 (en) | 2012-03-29 |
ECSP13012560A (es) | 2013-06-28 |
PE20171624A1 (es) | 2017-11-02 |
NZ608070A (en) | 2015-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013008017A2 (pt) | análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral | |
LTC2932970I2 (lt) | Antivirusinė terapija | |
BRPI1013643A2 (pt) | análogos de carba-nucleosídeo para tratamento antiviral | |
SMT201600476B (it) | Tenofovir alafenammide emifumarato | |
BRPI0911410A2 (pt) | análogos de carba-nucleosídeo para tratamento antiviral | |
DK2576534T3 (da) | 1-Substitueret-carba-nukleosid prodrugs til antiviral behandling | |
CO6791562A2 (es) | Compuestos antivirales | |
CO6930321A2 (es) | Curación de tejidos | |
BR112014007781A2 (pt) | compostos anti-virais | |
BR112015004373A2 (pt) | implante adequado para osteotomia do calcâneo | |
DE112012001607A5 (de) | Gurtaufroller | |
BR112013028856A2 (pt) | pinça para fixação de fraturas em ossos | |
JP2013527159A5 (ja) | イソフラボン抗ウイルス性化合物 | |
JP2013525368A5 (ja) | スルホンアミド抗ウイルス性化合物 | |
BR112013033974A2 (pt) | terapia de combinação | |
EP2713914A4 (en) | BONE WRIST | |
BR112014007599A2 (pt) | compostos anti-virais | |
BR112014015218A2 (pt) | sistemas de afastadores cirúrgicos | |
BR112014008505A2 (pt) | mecanismo de travamento | |
BR112013007492A2 (pt) | glicodendrímeros de polipropileterimina | |
CO6910201A2 (es) | Análogos de pirazol sustituidos | |
FIU20114081U0 (fi) | Putkijalka | |
CL2014001638A1 (es) | Analogos de glucagon | |
CO7061032A2 (es) | Análogos de glucagón | |
ES1075381Y (es) | Taleguilla de torero de emergencia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B04C | Request for examination: application reinstated [chapter 4.3 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |